WO2019124854A1 - Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci - Google Patents

Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci Download PDF

Info

Publication number
WO2019124854A1
WO2019124854A1 PCT/KR2018/015687 KR2018015687W WO2019124854A1 WO 2019124854 A1 WO2019124854 A1 WO 2019124854A1 KR 2018015687 W KR2018015687 W KR 2018015687W WO 2019124854 A1 WO2019124854 A1 WO 2019124854A1
Authority
WO
WIPO (PCT)
Prior art keywords
fraction
dry eye
eye syndrome
licorice
extract
Prior art date
Application number
PCT/KR2018/015687
Other languages
English (en)
Korean (ko)
Inventor
김진숙
김찬식
김영숙
조규형
이익수
김정현
Original Assignee
한국한의학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국한의학연구원 filed Critical 한국한의학연구원
Publication of WO2019124854A1 publication Critical patent/WO2019124854A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient, and a health functional food for preventing or ameliorating dry eye syndrome comprising the mixed extract or the fraction thereof as an active ingredient .
  • Dry eye syndrome is not simply a tear defect, but it causes eye discomfort, eye fatigue, decreased visual acuity, and instability of the tear layer due to inflammation of the tear and ocular surface (cornea and conjunctiva) .
  • inflammation plays an important role in infiltration of inflammatory cells, increased expression of immune activation molecules and adhesion molecules, Th1 and Th17 responses, abnormalities of apoptotic markers and chemokines have.
  • dry eye syndrome is a common disease that occurs in about 20% of adults in Korea. Especially, global warming due to global climate change, especially El Ni ⁇ o phenomenon, and environmental pollution such as fine dust, There is no therapeutic or functional food.
  • Paeonia lactiflora is a perennial plant belonging to the family Paeoniaceae and is native to parts of China, Siberia and Korea, and the herbal medicine and herbal medicines are defined as the roots of Paeonia lactiflora Pallas or other herbaceous plants .
  • the pharmacological activities of peonies have been reported to inhibit platelet aggregation, to act on the circulatory system, to antitumor action, and to enhance immunity (Son Dong-Ju, Journal of the Korean Society of Food Science and Nutrition, 2002, 31, 511, 4, 445).
  • Licorice ( Glycyrrhiza uralensis ) is a perennial herbaceous plant belonging to the soybean family.
  • the pharmacological activity of licorice was evaluated by the antitumor effect of chronic hepatitis improvement, antidiabetic effect (Mae, Tatsumasa, et al., The Journal of nutrition 133.11 (2003): 3369-3377) , Korean Journal of Plant Resources 27.5 (2014): 401-414.), Ulcerative Colitis Inhibitory Effect (Lee, Keyong-Ho, and Ki-Hyeong Rhee., The Korean Journal of Food and Nutrition 23.4 -439.), Antioxidant effects (Woo, Koan-Sik, et al., Journal of the Korean Society of Food Science and Nutrition 36.6 (2007): 689-695).
  • the present inventors have completed the present invention by confirming that a mixed extract of peony root and licorice, or a fraction thereof, can treat dry eye syndrome through an increase in tear secretion amount and inhibition of corneal morphological change.
  • Another object of the present invention is to provide a composition for preventing or treating dry eye syndrome comprising a mixture of peony root and licorice root extract or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide a health functional food for preventing or ameliorating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
  • It is another object of the present invention to provide a feed composition for preventing or improving dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide a quasi-drug composition for the prevention or treatment of dry eye syndrome comprising a mixture of peony root and licorice root extract or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide an eye cosmetic additive composition for preventing or improving dry eye syndrome, which comprises a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide a method for preventing or treating dry eye syndrome comprising administering to a subject a mixed extract of licorice and licorice or a fraction thereof.
  • the peanut and licorice mixed extract of the present invention and the fractions thereof can be used for the development of a pharmaceutical composition for the prevention or treatment of dry eye syndrome since the amount of tear secretion due to dry eye syndrome and the change of corneal morphology can be significantly inhibited It will be possible.
  • FIG. 1 is a photograph showing a change in the amount of tear secretion according to the administration of the mixed extract through an eye volume test sheet.
  • FIG. 2 is a graph showing a quantitative change in the amount of tear secretion according to the mixed extract administration (*: p ⁇ 0.05 vs. Normal; #: p ⁇ 0.05 vs. dry eye).
  • FIG. 3 is a photograph showing changes in the corneal morphology of rats upon administration of mixed extracts.
  • FIG. 4 is a graph showing scores of corneal smoothness score in rats according to the mixed extract administration.
  • the corneal smoothness score was evaluated by dividing the corneal morphology by 0 to 5 (zero point: no distortion, 1 point: distortion at 1/4 point, 2 points: 2/4 point , 3 points: Distortion at 3/4 point, 4 points: Distortion at all points, 5 points: Uncertainty of rounded shape due to severe distortion, #: p ⁇ 0.05 vs. dry eye).
  • FIG. 5 is a graph showing a quantitative change in the amount of tear secretion according to administration of licorice extract (*: p ⁇ 0.05 vs. Normal).
  • FIG. 6 is a photograph showing changes in the corneal morphology of rats upon administration of licorice extract.
  • FIG. 7 is a graph showing the corneal smoothness score of rats according to administration of mixed extract (*: p ⁇ 0.05 vs. Normal).
  • the inventors of the present invention have found that when a variety of studies are conducted to develop a therapeutic agent capable of effectively treating dry eye syndrome, a mixed extract of peony root and licorice or a fraction thereof shows an effect of treating dry eye syndrome.
  • the above-mentioned mixed extracts or fractions of peanut and licorice not only significantly inhibited the decrease of tear secretion and changes in corneal morphology according to dry eye syndrome but also showed similar effects to the commercial drugs used for the treatment of dry eye syndrome there was.
  • the technique for treating dry eye syndrome using the mixed extract or fraction has not been known at all and has been developed for the first time by the present inventors.
  • the present invention provides a pharmaceutical composition for preventing or treating dry eye syndrome, which comprises a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
  • the present invention also provides a composition for preventing, ameliorating or treating dry eye syndrome, comprising a mixture of peony root and licorice, or a fraction thereof as an active ingredient.
  • the mixed extract of peanut and licorice having the preventive and therapeutic activity of dry eye syndrome can be extracted from various organs of natural, hybrid, and variant plants and can be extracted from various organs such as roots, stems, leaves, flowers, As well as extracts from plant tissue cultures.
  • Paeonia lactiflora is a perennial herb that belongs to the family Paeoniaceae and is native to parts of China, Siberia and Korea.
  • peonies are defined as the roots of Paeonia lactiflora or other plants, and peeled, dried and dried together with peel and peel are called peptone.
  • the pharmacological activities of peonies have been reported to inhibit platelet aggregation, to act on the circulatory system, to antitumor action, and to enhance immunity.
  • Glycyrrhiza uralensis is a perennial herbaceous plant belonging to the soybean family and may be used as a medicinal or sweetener by drying the roots.
  • the pharmacological activity of licorice has been reported to improve chronic hepatitis by detoxification, anti - diabetic effect, anti - ulcer effect, ulcerative colitis inhibitory effect, antioxidant effect.
  • the mixed extract may be extracted from roots, stems, leaves, flowers, or fruits of peony root and licorice, and is not particularly limited thereto.
  • the mixed extract of peony root and licorice includes, but is not limited to, extracts from a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixed solvents thereof.
  • the above extract may contain any one of the extract obtained by the extraction treatment, the diluted solution or the concentrate of the extract, the dried product obtained by drying the extract, or the adjusted product or the purified product.
  • the alcohol may be butyl alcohol, ethyl alcohol, methyl alcohol or a water-soluble alcohol thereof.
  • the water-soluble alcohol may be an alcohol in an amount of 0.1 to 100% by weight.
  • fraction means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
  • the fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art.
  • a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting a mixed extract of peony root and licorice root is not particularly limited and may be carried out according to a method commonly used in the art.
  • the fraction may be a hexane fraction, an ethyl acetate fraction, a butanol fraction or a water fraction of a mixture of peony root and licorice.
  • the fractions may each comprise 0.01 to 100% by weight, more specifically 1 to 80% by weight, based on the total weight of the pharmaceutical composition.
  • the kind of the fraction solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used.
  • Non-limiting examples of the fraction solvent include polar solvents such as water and alcohol; And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more.
  • polar solvents such as water and alcohol
  • non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more.
  • C1 to C4 alcohols can be specifically used.
  • dry eye syndrome refers to dry eye syndrome, which is caused by inflammation of the lacrimal gland and decongestion of the cornea, inhibiting tear secretion, And abnormal conjunctival epithelial disorder caused by excessive dryness of the tears due to the dry eye syndrome and resulting in wounds of the cornea.
  • prevention refers to any act that inhibits or delays the symptoms of dry eye syndrome by administration of a composition comprising the peony root extract of licorice and licorice, or fractions thereof, according to the present invention.
  • treatment refers to any action that improves or alleviates the symptoms of dry eye syndrome by administration of a composition comprising the peony root extract and licorice root extract or fractions thereof according to the present invention.
  • the composition may increase the secretion amount of tears or inhibit the morphological change of the cornea.
  • the morphological change of the cornea may be due to excessive irritation of the tears, which may cause the surface of the cornea to become rugged and the rounded circle to warp and distort.
  • the composition of the present invention may improve smoothness and flatness.
  • the tear secretion amount was significantly increased in all the concentration groups when the mixed extract of peony root and Licorice was administered, and it was confirmed that the effect was increased depending on the concentration (FIGS. 1 and 2 ).
  • the term "pharmaceutical composition” means a preparation intended for the prevention or treatment of disease, and may be formulated into various forms according to each ordinary method.
  • it can be formulated into a form such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and the like, and can be formulated in the form of external preparations, suppositories and sterilized injection solutions.
  • it can be formulated into an external preparation for eye, a form suitable for topical administration, for example, an eye drop, a cream, an ointment, a gel or a lotion.
  • composition of the present invention may be prepared in the form of a pharmaceutical composition for preventing or treating dry eye syndrome, which further comprises an appropriate carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, (non-naturally occuring carrier).
  • the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
  • Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
  • the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
  • the dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction to the disease, the age, body weight, sex, history, or kind of the substance used as the active ingredient.
  • the pharmaceutical composition of the present invention may be administered at a dose of from about 0.1 ng to about 1,000 mg / kg, in particular from 1 ng to 1,000 mg / kg, per adult, and the frequency of administration of the composition of the present invention is specifically limited However, it may be administered once a day or divided into several doses. The dose is not intended to limit the scope of the invention in any way.
  • the present invention provides a method for treating dry eye syndrome comprising administering the pharmaceutical composition to a subject suffering from dry eye syndrome in a pharmaceutically effective amount.
  • the term "individual” as used herein may include, without limitation, mammals including rats, livestock, and the like with dry eye syndrome.
  • the "individual” may include companion animals.
  • the companion animal refers to an animal living together with a human, and specific examples include, but are not limited to, mammals such as dogs, cats, hamsters, and guinea pigs, and birds such as parrots and canaries.
  • composition may be administered in single or multiple doses in a pharmaceutically effective amount.
  • the administration route of the pharmaceutical composition for preventing or treating dry eye syndrome of the present invention can be administered through any ordinary route as long as it can reach the target tissue.
  • composition of the present invention may be administered orally, intraperitoneally, intramuscularly, subcutaneously, intradermally, transdermal patch, oral, intranasal, intrapulmonary, Intramuscular administration, intrathecal administration, intrarectal administration, and the like, and specifically administered orally.
  • the present invention provides a health functional food for preventing or ameliorating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
  • peanut, licorice, fraction, and dry eye syndrome in the health functional food of the present invention is as defined above.
  • the term “improvement” means any action that alters or modifies dryness of the eye by orally administering the composition.
  • the term "functional" as used in the present invention means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action.
  • the health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art.
  • the formulation of the health functional food may also be produced without limitation as long as the formulation is recognized as a health functional food.
  • the health functional food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has advantages of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to improve the effect of preventing or improving dry eye syndrome.
  • the health functional food is a food prepared by adding the mixed extract or fraction of the present invention to a food material such as beverage, tea, spice, gum, confectionery, or the like, or encapsulating, powdering, or suspending, But it has the advantage that there is no side effect that can occur when a drug is taken for a long time using a food as a raw material, unlike a general medicine.
  • an eye cosmetic additive composition for preventing or improving dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
  • the definition of the extract of Eisenhower extract, fraction, dry eye syndrome, prevention and improvement in the eye cosmetic additive composition is as defined above.
  • the additive may be included in eye make-up products and may be effective in preventing or improving the disease.
  • the composition may include eye make-up products.
  • eye make-up cosmetic products include any one selected from the group consisting of eye pencil, eye liner, eye shadow, mascara, and eye makeup remover. have.
  • a quasi-drug composition for preventing or improving dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
  • Quasi-drug product in the present invention means products which are less active than drugs, for example, for the purpose of diagnosing, treating, improving, alleviating, treating or preventing a disease in a human or an animal.
  • Quasi-drugs are products that are not used for medicines, such as fibers and rubber products used for the treatment and prevention of diseases of humans and animals, and are not acting directly or indirectly on the human body, These include sterilization and insecticides to prevent infectious diseases.
  • the type and formulations of the quasi-drug composition of the present invention are not particularly limited, but may be disinfectant cleaner, shower foam, gagrin, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
  • a feed composition for preventing or ameliorating dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
  • feed means any natural or artificial diet, single meal or the like or ingredients of the above formula for ingesting, ingesting, digesting or suitable for the individual.
  • the kind of the feed is not particularly limited, and feeds conventionally used in the art can be used.
  • feeds include vegetable feeds such as cereals, muscle roots, food processing busines logistics, algae, fibers, pharmaceuticals, buses, oils, pastes, pulses or cereals; Animal feeds such as proteins, inorganic substances, fats, oils, fats, oils, monocellular proteins, animal plankton or foods. These may be used alone or in combination of two or more.
  • the tear secretion amount was significantly increased in all the concentration groups when the mixed extract of peony root and Licorice was administered, and it was confirmed that the effect was increased depending on the concentration (FIGS. 1 and 2 ).
  • the above-mentioned results indicate that the mixed extract of peony root and licorice or its fractions can be used as a pharmaceutical composition for preventing dry eye disease or eye fatigue, for improving or ameliorating eye fatigue, a health functional food, an eye cosmetic additive, And it can be used effectively.
  • the extracts were filtered, and the filtrate was concentrated under reduced pressure at about 50 ° C and dried to prepare a mixed extract.
  • the experimental group consisted of the following: non-invasive normal group (NOR) with no abnormality, the disease caused by dry eye lacrimal gland by the method of Example 2.1 (JGT-50) administered with 50 mg / kg of the mixed extract of the present invention (JGT), a drug administration group (JGT-50) administered with 100 mg / kg of the mixed extract of the present invention (JGT- 100), the drug-administered group (JGT-250) in which 250 mg / kg of the mixed extract of the present invention (JGT) was administered.
  • the drug containing the mixed extract of the present invention was prepared by dissolving the above dose in sterilized physiological saline containing 0.5% DMSO.
  • the dry eye was additionally administered on the 5th day for 3 days.
  • the animals were anesthetized and the change in color of the test strip was measured by tearing after 30 seconds of contact with the phenol-red thread volume test (FCI Opthalmics Zone Quick, Japan) And the efficacy of the drug was evaluated.
  • composition of the test group and administration of the drug were carried out in the same manner as in Example 2.2.
  • the animals were anesthetized and photographed using a stereoscopic microsope (Olympus, Japan) equipped with a fiberoptic ring illuminator. Changes in corneal morphology were assessed by grading the degree of distortion of the rounded circle shape of the circular light reflected on the corneal epithelium from 0 to 5. 0 point: No distortion, 1 point: Distortion at 1/4 point, 2 points: Distortion at 2/4 point, 3 points: Distortion at 3/4 point, 4 points: Distortion at all points, 5 point: Distortion at severe point Can not recognize the shape of the round circle.
  • the morphological changes of the cornea were evaluated.
  • the tears secreted from the external lacrimal gland formed a tear film, and the smooth and flat surface state was maintained.
  • the smooth and flat surface state was maintained.
  • abnormalities in the tear film covering the cornea resulted in degeneration of the epithelium of the corneal epithelium and smooth surface of the cornea, so that the rounded shape was distorted and distorted.
  • JGT-100 and JGT-250 significantly inhibited corneal morphological changes such as the disease group (FIGS. 3 and 4).
  • the tear secretion amount was measured using the method of Example 2.2 in order to confirm the therapeutic effect of the licorice extract extracted by the method of Example 1 with dry liquorice alone.
  • the dose of licorice extract was 84 mg / kg, the dose of Licorice based on JGT-250 (250 mg / kg dose).
  • the tear secretion amount of the licorice extract-treated group was not significantly different from that of the dry eye syndrome group, confirming that the licorice extract did not increase the tear secretion amount.
  • Example 2.3 In order to confirm the therapeutic effect of dry eye extract of licorice root extract, the change of corneal morphology was confirmed by the method of Example 2.3.
  • the dose of licorice extract was 84 mg / kg, the dose of Licorice based on JGT-250 (250 mg / kg dose).
  • the licorice extract alone did not affect the amount of tear secretion, and had no effect of inhibiting the corneal morphological change. Thus, it was confirmed that it was not suitable as a composition for treating dry eye syndrome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant, en tant que principe actif, un extrait mixte de Paeonia lactiflora et Glycyrrhiza uralensis ou une fraction de celui-ci, et un aliment santé fonctionnel pour prévenir ou soulager le syndrome de sécheresse oculaire, contenant, en tant que principe actif, l'extrait mixte ou une fraction de celui-ci. L'extrait mixte de Paeonia lactiflora et Glycyrrhiza uralensis ou une fraction de celui-ci de la présente invention peut inhiber de manière significative une réduction de la sécrétion de larmes et des changements topographiques de la cornée, provoqués par le syndrome de sécheresse oculaire, et peut donc être fourni en tant que principe actif d'une composition pharmaceutique et d'un aliment santé fonctionnel pour prévenir ou traiter le syndrome de sécheresse oculaire et dans une méthode de traitement.
PCT/KR2018/015687 2017-12-22 2018-12-11 Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci WO2019124854A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0178782 2017-12-22
KR1020170178782A KR102070850B1 (ko) 2017-12-22 2017-12-22 혼합 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2019124854A1 true WO2019124854A1 (fr) 2019-06-27

Family

ID=66993602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015687 WO2019124854A1 (fr) 2017-12-22 2018-12-11 Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci

Country Status (2)

Country Link
KR (1) KR102070850B1 (fr)
WO (1) WO2019124854A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102466377B1 (ko) * 2020-06-19 2022-11-14 대한민국(농촌진흥청장) 꽃양귀비 추출물 또는 이의 분획물을 유효성분으로 함유하는 안구건조증 또는 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물
KR20220131018A (ko) 2021-03-19 2022-09-27 주식회사 티스템 무막줄기세포추출물을 포함하는 안구건조증 치료용 조성물 및 이에 의해 제조된 점안액

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
CN102210821A (zh) * 2011-05-15 2011-10-12 王春兰 一种治疗干眼症的中药
CN104383296A (zh) * 2014-12-04 2015-03-04 湖南中医药大学 一种用于治疗干眼症的中药组合物及其制备方法
CN104435685A (zh) * 2014-11-30 2015-03-25 顾蔷怡 一种治疗干眼症的药物及其制备方法
KR20170004245A (ko) * 2015-07-01 2017-01-11 김무연 안과 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160025187A (ko) * 2014-08-27 2016-03-08 우용규 황백 추출물을 이용한 피부냉감용 생약조성물 및 이의 제조방법과 이를 이용한 피부개선제품

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
CN102210821A (zh) * 2011-05-15 2011-10-12 王春兰 一种治疗干眼症的中药
CN104435685A (zh) * 2014-11-30 2015-03-25 顾蔷怡 一种治疗干眼症的药物及其制备方法
CN104383296A (zh) * 2014-12-04 2015-03-04 湖南中医药大学 一种用于治疗干眼症的中药组合物及其制备方法
KR20170004245A (ko) * 2015-07-01 2017-01-11 김무연 안과 질환의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
KR102070850B1 (ko) 2020-01-29
KR20190076732A (ko) 2019-07-02

Similar Documents

Publication Publication Date Title
WO2010104309A2 (fr) Compositions pour prévenir ou améliorer des maladies gastro-intestinales
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2021049864A1 (fr) Composition permettant d'améliorer le syndrome de l'œil sec contenant un extrait d'aralia elata
WO2019124854A1 (fr) Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci
KR101764786B1 (ko) 호장근 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 및 치료용 조성물
WO2019146881A1 (fr) Composition pour la prévention ou le traitement du syndrome de l'œil sec, contenant un extrait d'aucuba japonica
WO2018026103A1 (fr) Composition pour la régénération cellulaire comprenant un extrait d'axe floral de ginseng
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2018164325A1 (fr) Composition permettant de soigner les symptômes du syndrome climatère féminin
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
WO2018230942A1 (fr) Composition contenant un extrait ou une fraction d'extrait de reynoutria japonica pour prévenir et traiter le syndrome de l'œil sec
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2017176001A1 (fr) Composition destinée à soulager les symptômes de la ménopause chez les femmes, contenant de l'extrait de sasa quelpaertensis nakai
WO2011139118A2 (fr) Composition pharmaceutique et composition d'aliment naturel fonctionnel pour la prévention, le traitement ou l'amélioration de maladies de type dyskinésie gastro-intestinale
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2016129902A1 (fr) Composition pour prévenir, soulager ou traiter le syndrome d'épuisement professionnel
WO2020116996A1 (fr) Composition pharmaceutique contenant un extrait d'aucuba japonica pour prévenir ou traiter la dégénérescence maculaire
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2019098615A1 (fr) Composition contenant un extrait ou une fraction d'extrait d'aster k oraiensis pour la prévention ou le traitement de l'œil sec
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2017069506A1 (fr) Composition pharmaceutique pour la prévention et le traitement de symptômes de ménopause, contenant, comme principe actif, un mélange d'extraits de réglisse et de curcuma longa
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
KR100807645B1 (ko) 위장질환 치료 및 예방용 조성물 및 그의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18892418

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18892418

Country of ref document: EP

Kind code of ref document: A1